In-vitro activities of essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021
Using aztreonam/avibactam, eravacycline and colistin to treat infections caused by CRB offers significant advantages. These findings will guide clinical practice and optimize antimicrobial administration.
Authors
- Wei Kang
- Jingjia Zhang (ORCID: https://orcid.org/0000-0002-8285-950X)
- Yun Wu (ORCID: https://orcid.org/0009-0000-3906-398X)
- Hongli Sun (ORCID: https://orcid.org/0000-0001-8398-3011)
- Ge Zhang (ORCID: https://orcid.org/0000-0002-3116-3246)
- Jin Li (ORCID: https://orcid.org/0000-0002-3330-0160)
- Yali Liu (ORCID: https://orcid.org/0000-0002-3160-8129)
- Tong Wang (ORCID: https://orcid.org/0000-0002-1828-5935)
- Yingchun Xu (ORCID: https://orcid.org/0000-0002-9457-5635)
- Jiawei Chen (ORCID: https://orcid.org/0000-0002-9110-2509)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- International Journal of Antimicrobial Agents
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1016/j.ijantimicag.2024.107341
- Citations
- 26
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 4.43